RKI983

· Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for RKI983, covering 2020-12-19 to 2020-12-19. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension [Phase 1, Phase 2]

See pricing